Profile data is unavailable for this security.
About the company
Racura Oncology Ltd, formerly Race Oncology Limited, is an Australia-based Phase III clinical biopharmaceutical company with a focus on cancer care. The Company's lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA and RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterized safety profile. The Company is advancing a formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with Phase III clinical programs in acute myeloid leukemia (AML), a Phase I a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase I a/b program in combination with the anthracycline doxorubicin, where the Company is focused on delivering both cardioprotection and enhanced anticancer activity for solid tumor patients.
- Revenue in AUD (TTM)788.42k
- Net income in AUD-4.79m
- Incorporated2011
- Employees--
- LocationRacura Oncology LtdLevel 36, Gateway 1, Macquarie PlaceSYDNEY 2000AustraliaAUS
- Phone+61 28051-3043
- Websitehttps://www.raceoncology.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Frontage Holdings Corp | 356.69m | 5.41m | 367.36m | 1.54k | 67.72 | 0.7629 | 6.47 | 1.03 | 0.0148 | 0.0148 | 0.9733 | 1.31 | 0.4545 | 60.36 | 3.97 | 1,267,207.00 | 0.6902 | 3.05 | 0.8654 | 3.64 | 27.78 | 32.14 | 1.52 | 6.84 | 1.22 | 1.97 | 0.2861 | 0.00 | -1.90 | 20.48 | -92.68 | -46.72 | 13.29 | -- |
| Mabpharm Ltd | 86.13m | -5.58m | 372.06m | 383.00 | -- | 18.52 | 56.17 | 4.32 | -0.0075 | -0.0075 | 0.1158 | 0.027 | 0.4209 | 0.4659 | 4.05 | 1,515,415.00 | -2.73 | -19.62 | -4.02 | -25.69 | 86.40 | -- | -6.48 | -211.59 | 0.6906 | -1.58 | 0.7552 | -- | 196.27 | -- | 38.89 | -- | -12.13 | -- |
| Cogstate Ltd | 75.68m | 14.46m | 372.27m | 61.00 | 26.10 | 5.37 | 19.95 | 4.92 | 0.0831 | 0.0831 | 0.4349 | 0.4042 | 0.866 | -- | 4.69 | -- | 16.55 | 11.82 | 20.98 | 16.38 | 60.53 | 56.32 | 19.11 | 14.87 | -- | -- | 0.0097 | -- | 22.25 | 18.44 | 86.15 | -- | -0.4007 | -- |
| Healios KK | 877.40k | -35.19m | 383.13m | 65.00 | -- | 14.40 | -- | 436.66 | -39.54 | -39.54 | 0.9577 | 25.42 | 0.0065 | -- | 0.6218 | 1,492,308.00 | -25.92 | -24.31 | -37.79 | -30.77 | -77.32 | -- | -4,018.56 | -2,817.04 | -- | -6.50 | 0.7028 | -- | 362.81 | 44.46 | -10.78 | -- | 19.31 | -- |
| Heartseed Inc | 23.88m | 4.70m | 390.37m | 39.00 | 82.53 | 5.97 | 157.15 | 16.35 | 22.88 | 22.88 | 116.95 | 316.02 | 0.3697 | -- | 22.10 | 67,685,900.00 | 7.27 | -- | 7.61 | -- | -- | -- | 19.67 | -- | 20.40 | -- | 0.0003 | -- | 153.42 | -- | 44.84 | -- | -- | -- |
| Hanx Biopharmaceuticals (Wuhan) Co Ltd | -18.04bn | -18.04bn | 392.27m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -52.30 | -- | -- | -- |
| Racura Oncology Ltd | 788.42k | -4.79m | 415.67m | -- | -- | 24.85 | -- | 527.22 | -0.0282 | -0.0282 | 0.0043 | 0.0922 | 0.0418 | -- | 11.64 | -- | -25.38 | -41.75 | -27.84 | -44.07 | -- | -- | -607.20 | -2,015.76 | -- | -- | 0.00 | -- | -5.30 | 142.92 | 65.36 | -- | -- | -- |
| Antengene Corp Ltd | 17.14m | -46.44m | 416.70m | 152.00 | -- | 2.68 | -- | 24.31 | -0.4142 | -0.4142 | 0.1529 | 1.27 | 0.0619 | 1.51 | 3.20 | 562,035.80 | -16.77 | -48.14 | -19.52 | -53.06 | 78.54 | -- | -271.00 | -1,460.93 | 4.41 | -- | 0.2346 | -- | 36.62 | -- | 45.07 | -- | 259.46 | -- |
| Jiangsu Recbio Technology Co Ltd | 2.21m | -132.86m | 423.51m | 507.00 | -- | 11.51 | -- | 191.26 | -1.54 | -1.54 | 0.0257 | 0.4223 | 0.006 | -- | -- | 23,112.25 | -36.26 | -31.31 | -64.03 | -37.31 | -- | -- | -5,990.59 | -- | 0.2767 | -100.74 | 0.8254 | -- | -- | -- | 1.67 | -- | 16.82 | -- |
